GlassScriptPhysician profile
Chrisanthy Ory
NPI 1821758806
$1,361.24
in general payments reported to CMS, 2019-2025
16 companies · $454 in 2025
The $454 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $133 · 2023: $258 · 2024: $517 · 2025: $454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,228.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.02 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $198.41 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $183.55 | 2024-2025 | |
| Lilly USA, LLC | $156.81 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $91.06 | 2024-2025 | |
| Exact Sciences Corporation | $82.98 | 2023-2024 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.11 | 2023-2024 | Xifaxan |
| Abbvie INC. | $59.82 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $51.37 | 2025 | Voquezna |
| Otsuka America Pharmaceutical, INC. | $41.48 | 2023-2025 | Rexulti, Nuedexta |
| Amgen INC. | $36.84 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Alk-Abello, INC | $22.75 | 2024 | Odactra, Ragwitek, Grastek |
| Abbott Laboratories | $21.87 | 2023 | Freestyle Libre 3 |
| Dexcom, INC. | $21.01 | 2025 | Dexcom G6 Transmitter |
| Renalytix Ai, INC. | $17.32 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $14.84 | 2025 | Veozah |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrisanthy Ory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.